On the Record · Tempus AI
Tempus AI acquisitions, on the record
The businesses Tempus AI bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Ambry Genetics CorporationWord for word“Pursuant to the terms of the Purchase Agreement, consideration for the Acquisition consisted of $375.0 million in cash, subject to adjustment for cash, unpaid indebtedness, unpaid transaction expenses and net working capital of Ambry, or Cash Consideration, plus an aggregate of 4,483,136 shares of our Class A common stock, or the Stock Consideration, all of which shares were issued by us to the Seller on February 3, 2025, upon the closing of the Acquisition, and 2,152,505 of which shares are subject to a lock-up for a period of one year following the closing date of the Acquisition.” 10-K for 2024 | agreed acquisition | — | — |
Highline Consulting, LLCWord for word“In January 2022, we acquired Highline Consulting, LLC, a contract research organization, or CRO, which we subsequently renamed Tempus Compass, LLC, or Tempus Compass.” 10-K for 2024 | acquisition | In January 2022 | — |
Arterys, Inc.Word for word“In October 2022, we acquired Arterys, Inc., a company that provides a platform to derive insights from radiologic medical images to improve diagnostic decision-making, efficiency, and productivity across multiple disease areas.” 10-K for 2024 | acquisition | In October 2022 | — |
SEngine Precision Medicine LLCWord for word“SEngine Precision Medicine LLC (including its predecessor corporation SEngine Precision Medicine, Inc.), or SEngine, a company we acquired on October 3, 2023, received a letter from an attorney representing HUB Organoids IP B.V., or HUB Organoids, which states that SEngine’s PARIS ® test methodologies “appear to share similarities with methods that the HUB has used in its own organoid 93 work.”” 10-K for 2024 | acquisition | October 3, 2023 | — |
OneOme, Inc.Word for word“Our acquisition of OneOme, Inc., or OneOme, in November 2025 further enhanced our ability to provide pharmacogenetics tests, such as DPYD.” 10-K for 2025 | acquisition | November 2025 | — |
Paige, Inc.Word for word“In August 2025, we acquired Paige, Inc., or Paige, a company specializing in digital pathology.” 10-K for 2025 | acquisition | August 2025 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2022-12-31 | $39.6 million | — |
| 2023-12-31 | $5.7 million | $20.2 million |
| 2024-12-31 | $0 | — |
| 2025-12-31 | $376.7 million | $396.7 million |
Deal filings since 2016
- 2026-07-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-05-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-07-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-02-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-11-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Tempus AI’s annual reports (10-K for 2025, 10-K for 2024) and the financial data it files with the SEC, as of 2026-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.